Hematology/Oncology

Top Story

Recombinant FVIII with extended half life safe, effective for hemophilia A

September 1, 2015

BAX 855, a pegylated, full-length recombinant Factor VIII, appeared safe and effective for the biweekly prophylactic treatment of patients with hemophilia A, according to the results of a phase 2/phase3 study.

“Patients with hemophilia A who adopt a prophylactic regimen can reduce their bleeding rate, and thus reduce the probability of developing chronic arthropathy, which leads to disability,” Barbara A. Konkle, MD, professor of medicine at Puget Sound Blood Center and University of Washington, and colleagues wrote. “Current management of severe hemophilia A (factor VIII < 1% of normal) includes on-demand treatment for bleeding episodes and prophylaxis.”

Researchers find unsuspected DNA virus associated with HCC In the Journals

Researchers find unsuspected DNA virus associated with HCC

September 1, 2015
Adeno-associated virus type 2, a type of DNA virus, was associated with oncogenic insertional mutagenesis in human hepatocellular carcinoma cells, according to data…
FDA News

FDA grants priority review to elotuzumab for multiple myeloma

September 1, 2015
The FDA granted priority review to elotuzumab for the treatment of patients with multiple myeloma who have received at least one prior therapy, according to a press…
In the Journals

Nonmelanoma skin cancer in children, young adults associated with risk factors

September 1, 2015
Almost half of children and young adults with nonmelanoma skin cancer were exposed to risk factors, according to recently published study results.Researchers in Boston…
In the Journals

Precision medicine techniques show promise for pediatric patients with relapsed, refractory cancer

September 1, 2015
The incorporation of integrative clinical sequencing data into the management of relapsed, refractory or rare cancers in children or young adults appeared feasible and…
More News Headlines »
CME
Immunotherapy Updates 2015: FOCUS on NSCLC

Immunotherapy Updates 2015: FOCUS on NSCLC

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for…
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
CME
Hematology Oncology Case Consults

The Patient with Chronic Lymphocytic Leukemia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with chronic lymphocytic leukemia.
More »